NEXIUM® in the treatment of moderate and severe erosive esophagitis
Study identifier:D9612L00062
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Multicenter, Double-Blind, Randomized Trial of the Relationship of Intragastric Acid Control and Healing Status of Moderate and Severe Erosive Esophagitis After Treatment with Esomeprazole Magnesium (NEXIUM®) 10 mg and 40 mg Once Daily
Medical condition
Erosive Esophagitis
Phase
Phase 4
Healthy volunteers
No
Study drug
esomeprazole magnesium (oral medication)
Sex
All
Actual Enrollment
120
Study type
Interventional
Age
18 Years - 75 Years
Date
Study Start Date: 01 Jun 2004
Primary Completion Date: -
Study Completion Date: 01 Aug 2005
Study design
Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Other
Verification:
Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
Nexium Medical Science Director
AstraZeneca
